Skip to main content

Table 4 Healthcare resource utilization and economic impact of incontinence

From: Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS)

 

All patients

Incontinence episode per day

0

1

2–3

≥4

p-value

  N

625

162

165

177

121

Heath service utilization, mean number of visits over 6 month (SD)

Outpatient

1.42 (2.28)

1.30 (2.34)

1.35 (2.29)

1.48 (1.76)

1.61 (2.79)

0.484

  • Hospital

1.01 (1.53)

0.80 (1.38)

0.95 (1.63)

1.16 (1.44)

1.13 (1.69)

0.073

  • Clinic

0.35 (1.30)

0.48 (1.67)

0.34 (1.40)

0.24 (0.68)

0.35 (1.29)

0.152

  • Oriental clinic

0.07 (0.66)

0.03 (0.25)

0.06 (0.55)

0.07 (0.43)

0.13 (1.21)

0.289

Inpatient

0.05 (0.26)

0.06 (0.28)

0.06 (0.23)

0.03 (0.17)

0.09 (0.37)

0.736

  • Hospital

0.05(0.25)

0.05 (0.24)

0.05 (0.22)

0.03 (0.17)

0.09 (0.37)

0.537

  • Clinic

0.003 (0.06)

0.006 (0.08)

0.006 (0.08)

0

0

0.247

Emergency care

0.014 (0.13)

0.006 (0.08)

0.018 (0.13)

0.017 (0.13)

0.017 (0.18)

0.462

Incontinence pad use

  % of patients using incontinence pads

29.4

17.3

20.6

32.8

52.9

<0.0001

  Weekly cost of incontinence pads (SD)

KRW 1351 (8465)

KRW 227 (1032)

KRW 566 (1775)

KRW 863 (3014)

KRW 5259 (19320)

<0.0001

Work Productivity and Activity Impairment (WPAI) due to urinary incontinence

  % work time missed (SD)

2.9 (8.1)

0.6 (2.0)

1.4 (4.7)

4.2 (9.6)

7.0 (12.9)

0.001

  % regular activity impairment (SD)

29.0 (28.4)

21.2 (24.3)

26.0 (27.4)

31.5 (31.0)

44.8 (26.9)

0.001

Willingness of patients to try medical proceduresa to improve urinary symptoms

  % Willing to try

47.5

37.7

41.2

52.0

62.8

<0.0001

  1. aIncludes sacral neuromodulation, botulinum toxin injections, electrical stimulation, biofeedback training, bladder denervation, detrusor myomectomy, percutaneous tibial nerve stimulation